RGL4

Across TCGA pan-cancer cohorts, RGL4 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RGL4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher RGL4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGL4 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

COAD, LUSC, and SARC are the cancer types where RGL4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	All	0.149	0.678	<.001	21	view →
LUSC	DFS	Median	II,III,IV	0.124	0.709	.002	18	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
UCEC	OS	Median	IV	0.346	0.764	<.001	6	view →
LUAD	DFS	Median	All	0.244	0.767	.028	3	view →
SKCM	DFS	Median	II,III,IV	0.729	0.210	.022	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RGL4–COAD (OS)

Open the COAD breakdown →